Holds one active US DMF and one valid CEP for erlotinib, filing since 2012. Its 2025 FDA inspection closed as NAI, and its GMP is recognised in 23 markets.
Holds 2 active US DMFs and one valid CEP for erlotinib, filing since 2013. Its 2025 FDA inspection closed as VAI, and its GMP is recognised in 26 markets.
Holds one active US DMF for erlotinib, filing since 2012. Its 2022 FDA inspection closed as NAI, and its GMP is recognised in 13 markets.
Holds one active US DMF for erlotinib, filing since 2015. Its 2025 FDA inspection closed as VAI, and its GMP is recognised in 34 markets.
Holds one active US DMF for erlotinib, filing since 2016. Its 2025 FDA inspection closed as VAI, and its GMP is recognised in 18 markets.
Holds 2 active US DMFs for erlotinib, filing since 2020. Its 2025 FDA inspection closed as VAI, and its GMP is recognised in 13 markets.
Holds 2 active US DMFs for erlotinib, filing since 2008. Its 2025 FDA inspection closed as VAI, and its GMP is recognised in 15 markets.
Holds one active US DMF for erlotinib, filing since 2015. Its 2025 FDA inspection closed as NAI, and its GMP is recognised in 1 market.
Holds 2 active US DMFs for erlotinib, filing since 2018. Its GMP is recognised in 1 market.
Registered with SFDA (Saudi Arabia) for erlotinib.
The names are listed below. The filings, inspection history and GMP certificates behind each one are available with a free account.
This page filters the worldwide Erlotinib manufacturer list to companies based in India. The order is set by active filings weighted by regulator, inspection outcomes and their recency, breadth of GMP recognition, and evidence of real exports, less any open risk flags. Read the full method.
Tell us which markets you need to file in. These suppliers come back tiered for those markets, with the price corridor and an RFI sheet.
Start for free